Cancer News and Research

Latest Cancer News and Research

Phase II data from resminostat SAPHIRE study to be presented at International Hodgkin Lymphoma Symposium

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the presentation of Phase II data from Hodgkin Lymphoma patients treated in the 1st Simon Stage cohort of the ongoing SAPHIRE study with resminostat (4SC-201), an oral pan-histone deacetylase (HDAC) inhibitor, at the 8th International Symposium on Hodgkin Lymphoma in Cologne, Germany.

26 Oct 2010

Short course of radiation before surgery reduces rectal cancer recurrence: Study

Patients with cancer found at the end of the large intestine called the rectum who receive one week of radiation therapy before surgery have a 50 percent reduction in chance that their cancer will return after 10 years, according to a large, randomized study presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Genmab begins Phase III head to head study of ofatumumab vs. rituximab in follicular NHL

Genmab A/S announced today the start of a Phase III study of single agent ofatumumab compared to single agent rituximab in patients with follicular non-Hodgkin's lymphoma (NHL) that has relapsed at least 6 months after completion of treatment with a rituximab-containing regimen to which they responded.

26 Oct 2010

La Jolla Institute scientist wins Malpighi Medal for pioneering work in heart disease

Klaus Ley, M.D, a scientist at the La Jolla Institute for Allergy & Immunology, was recently awarded the prestigious Malpighi Medal at the World Congress for Microcirculation in Paris, France. A lifetime achievement award presented by the European Society for Microcirculation, Dr. Ley received the honor in recognition of his pioneering endeavors in vascular immunology, a scientific discipline that he helped to pioneer, which looks at novel immune-based approaches to combating heart disease. He is only the 17th recipient of the biennial award worldwide.

26 Oct 2010

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Celtic Therapeutics Holdings L.P. a successor firm to Celtic Pharma, and Resolvyx Pharmaceuticals, Inc. (Resolvyx) announced today that they have entered into an option agreement relating to Resolvyx's RX-10045, a late-stage program for the treatment of dry eye syndrome and other ophthalmic conditions.

26 Oct 2010

TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that new data on TRC105 and TRC102 will be presented at the 22nd Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

26 Oct 2010

John Theurer Cancer Center unveils new $130M, 155,000-square-foot comprehensive facility

The John Theurer Cancer Center at Hackensack University Medical Center unveiled a new $130-million, 155,000-square-foot comprehensive cancer facility that will enhance the cancer center's ability to deliver multidisciplinary extraordinary care, best-in-class clinical quality, and cutting-edge research. The doors will open for patients in January 2011.

26 Oct 2010

Combination of radiation and hormone therapy improves survival rate among prostate cancer patients

Prostate cancer patients who are treated with a combination of hormone therapy and radiation have a substantially improved chance of survival compared to patients who do not receive radiation, according to interim results of the largest randomized study of its kind presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Salk discovers potential new target for MS

Scientists are closer to solving one of the many mysteries of multiple sclerosis and other demyelinating diseases, thanks to a recent study conducted at the Salk Institute for Biological Studies. The research revealed a previously unknown connection between two ion channels, which, when misaligned, can cause the many bizarre symptoms that characterize the condition.

26 Oct 2010

Chemoradiotherapy can reduce bladder cancer recurrence

A major bladder cancer trial, funded by Cancer Research UK, has shown that adding two commonly used chemotherapy drugs to traditional radiotherapy can reduce the chance of a patient's tumour coming back by a third.

26 Oct 2010

Duke Center releases online atlas of ultra-high-resolution mouse brain

The most detailed magnetic resonance images ever obtained of a mammalian brain are now available to researchers in a free, online atlas of an ultra-high-resolution mouse brain, thanks to work at the Duke Center for In Vivo Microscopy.

26 Oct 2010

Panasonic completes investment in CardioNexus

Panasonic Corporation of North America has completed an investment in CardioNexus Corporation, a portfolio company of Houston's Fairway Medical Technologies which works closely with the Texas Medical Center. The move is part of Panasonic's plans to establish itself as a global leader in Personalized Preventive Medicine. The investment follows on an earlier Panasonic initiative to establish a presence in the world's largest medical complex, the Texas Medical Center based in Houston.

From PHC Europe B.V. 26 Oct 2010

Maven Semantic updates Lymphocyte Cell Biology research database

Maven Semantic announces updates to their Lymphocyte Cell Biology research database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector.

26 Oct 2010

Aspirin reduces risk of death from prostate cancer

Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half, according to a large study presented on November 3, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego. The study involved more than 5,000 men with localized cancer whose disease had not spread beyond the prostate gland.

26 Oct 2010

ARIAD's oral ridaforolimus improves PFS in patients with metastatic endometrial cancer

Pharmaceuticals, Inc. today announced interim results of a randomized, open‐label, active-control multicenter Phase 2 study of oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic or recurrent endometrial cancer. Based on this interim analysis, the study demonstrated a statistically significant improvement in the primary endpoint of median progression-free survival (PFS) in patients receiving single-agent ridaforolimus compared to patients receiving standard-of-care treatment.

26 Oct 2010

IMRT minimizes gastrointestinal side effects of prostate cancer treatment

Men with prostate cancer treated with a specialized type of radiation called intensity modulated radiation therapy (IMRT) have fewer gastrointestinal complications compared to patients treated with conventional three-dimensional conformal radiotherapy (3D-CRT), according to a study presented November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Calif. budget comes in the nick of time for health centers; LA. Gov. announces cuts in health care funding

With some California community health centers just weeks or days away from laying off staff or reducing their hours, the state adopted its latest-ever annual budget on Oct. 8.

26 Oct 2010

Researchers investigate impact of fungal toxin on birth defects

A Creighton University School of Medicine researcher has been awarded a $2.7 million grant by the National Institutes of Health (NIH) to investigate a possible link between the ingestion of tortillas and corn-based food products contaminated with a fungal toxin and increased risk for birth defects.

26 Oct 2010

Combination of chemotherapy and radiation improves control of cancer within bladder

Adding chemotherapy to radiation therapy for muscle invasive bladder cancer allows 67 percent of people to be free of disease in their bladders two years after treatment. This compares to 54 percent of people who receive radiation alone, according to the largest randomized study of its kind presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called OPTIMIZE that will evaluate twice-daily (BID) dosing of a telaprevir-based combination regimen in people chronically infected with genotype 1 hepatitis C virus (HCV) who have not been treated previously. This is the first Phase 3 study to evaluate twice-daily dosing of a protease inhibitor for the treatment of hepatitis C. OPTIMIZE will not include a control arm of pegylated-interferon and ribavirin alone.

26 Oct 2010

Cancer News and Research

Latest Cancer News and Research

Phase II data from resminostat SAPHIRE study to be presented at International Hodgkin Lymphoma Symposium

Short course of radiation before surgery reduces rectal cancer recurrence: Study

Genmab begins Phase III head to head study of ofatumumab vs. rituximab in follicular NHL

La Jolla Institute scientist wins Malpighi Medal for pioneering work in heart disease

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium

John Theurer Cancer Center unveils new $130M, 155,000-square-foot comprehensive facility

Combination of radiation and hormone therapy improves survival rate among prostate cancer patients

Salk discovers potential new target for MS

Chemoradiotherapy can reduce bladder cancer recurrence

Duke Center releases online atlas of ultra-high-resolution mouse brain

Panasonic completes investment in CardioNexus

Maven Semantic updates Lymphocyte Cell Biology research database

Aspirin reduces risk of death from prostate cancer

ARIAD's oral ridaforolimus improves PFS in patients with metastatic endometrial cancer

IMRT minimizes gastrointestinal side effects of prostate cancer treatment

Calif. budget comes in the nick of time for health centers; LA. Gov. announces cuts in health care funding

Researchers investigate impact of fungal toxin on birth defects

Combination of chemotherapy and radiation improves control of cancer within bladder

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in